Mayme Roettig
Nessuna posizione attualmente
Profilo
Mayme Lou Roettig is former Executive Medical Director at PLx Pharma, Inc. and former National Director at American Heart Association, Inc.
Ms. Roettig received an undergraduate degree from the University of Charleston and a graduate degree from Loyola University of Chicago.
Precedenti posizioni note di Mayme Roettig
Società | Posizione | Fine |
---|---|---|
PLX PHARMA WINDDOWN CORP. | Chief Tech/Sci/R&D Officer | 01/02/2023 |
American Heart Association, Inc.
American Heart Association, Inc. Miscellaneous Commercial ServicesCommercial Services American Heart Association, Inc. operates a voluntary health organization funded by private contributions. The organization offers services for coronary heart diseases and strokes, high blood cholesterol & physical inactivity, obesity, and diabetes. The company was founded in 1924 and is headquartered in Dallas, TX. | Corporate Officer/Principal | - |
Formazione di Mayme Roettig
Loyola University of Chicago | Graduate Degree |
University of Charleston | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 2 |
---|---|
American Heart Association, Inc.
American Heart Association, Inc. Miscellaneous Commercial ServicesCommercial Services American Heart Association, Inc. operates a voluntary health organization funded by private contributions. The organization offers services for coronary heart diseases and strokes, high blood cholesterol & physical inactivity, obesity, and diabetes. The company was founded in 1924 and is headquartered in Dallas, TX. | Commercial Services |
PLx Pharma, Inc.
PLx Pharma, Inc. Pharmaceuticals: MajorHealth Technology PLx Pharma, Inc. is a late-stage specialty pharmaceutical company, which engages in the development and commercialization of a technology platform for approved drugs. It offers the PLxGuard delivery system, which uses surface acting lipids, such as phospholipids and free fatty acids, to modify the physiochemical properties of various drugs with a targeted release to select portions of the gastrointestinal (GI) tract. The company was founded by Ronald R. Zimmerman on November 12, 2002 and is headquartered in Dover, DE. | Health Technology |